Please provide your email address to receive an email when new articles are posted on . KOLOA, Hawaii — In a panel discussion on different treatments for shoulder and upper extremity trauma presented ...

Venous thromboembolism, though rare in the community, is a major cause of death among hospitalized patients. It is estimated to cause 100,000 deaths per year and to contribute to mortality in another ...

Bristol-Myers Squibb and Pfizer announced that the FDA has accepted for review a supplemental New Drug Application (sNDA) for Eliquis (apixaban), for prophylaxis of deep vein thrombosis (DVT), which ...

Please provide your email address to receive an email when new articles are posted on . While I am a firm believer that aspirin is effective for the majority of our patients as a form of DVT and ...

New evidence-based guidelines from the American College of Chest Physicians (ACCP) recommend considering individual patients' risk of thrombosis when deciding for or against the use of preventive ...

PRINCETON, N.J. and NEW YORK — Bristol-Myers Squibb Co. and Pfizer announced that the Food and Drug Administration approved a supplemental new drug application for Eliquis (apixaban). The drug is a ...

Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients with cancer. Primary prevention with pharmacologic agents (or mechanical methods, if anticoagulants are ...

Missed doses of prophylactic anticoagulation account for much of the deep vein thrombosis (DVT) that occurs in surgery and trauma patients, a study showed. Among 202 such patients admitted to a level ...

Functional impairment (FI) after hematopoietic cell transplantation (HCT) and impact on quality of life (QOL). Bupropion for hot flashes control in breast cancer survivors: A prospective, double-blind ...

ThromboGenics NV and co-development partner BioInvent International announce that the first patient has been enrolled in the Phase II trial with their long-acting anticoagulant TB-402 for the ...

Most practicing orthopaedic surgeons currently use a pharmacologic agent as a means of prophylaxis for deep venous thrombosis and pulmonary embolism following total hip arthroplasty, total knee ...